Brandes Investment Partners 13F: Adds $40M to GRFS Stake
Brandes Investment Partners added over 5.3 million shares of Grifols, S.A. during the period.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brandes Investment Partners added 5,379,491 shares to its stake in Grifols, S.A. ($GRFS), a 17.38% increase, according to a 13F filing with the SEC dated May 15, 2026. It reported 36,333,714 shares worth $273.23 million at the end of the quarter.
Since the filing, $GRFS is up 4.1% after 1 week, down 0.5% after 1 month and up 1.1% to date (from the $7.56 close on May 15, 2026).
Find the original: Brandes Investment Partners 13F filings on SEC EDGAR
GRFS
Grifols, S.A.
Key Points
- Brandes Investment Partners increased its stake in Grifols, S.A. (NasdaqGS: GRFS) by 17.4% during the period, according to its latest SEC Form 13F filing.
- The institutional investor added 5,379,491 shares to bring its total holding to 36,333,714 shares.
- The ending position was valued at approximately $273.2 million based on the reporting period.
Get $GRFS trade alerts by text
We text you when insiders, Congress or big funds trade $GRFS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Grifols, S.A. alert may contain errors. Disclosures
Brandes Investment Partners Boosts Grifols Stake
Brandes Investment Partners filed its latest Form 13F with the SEC, revealing an increased position in Grifols, S.A. (NasdaqGS: GRFS). The firm raised its investment by 17.4%, lifting its total holdings during the period.
Inside the 17.4% Position Increase
The fund added 5,379,491 shares to its portfolio, bringing its total stake to 36,333,714 shares. In the previous filing period, the firm held 30,954,223 shares. Based on reporting figures, the updated position was valued at approximately $273.2 million.
Grifols Stock Background
The shares recently traded around $7.52, sitting between a 52-week low of $6.96 and a high of $10.23. The company carries a price-to-earnings ratio of 9.68 alongside a forward P/E of 5.10.
About Grifols, S.A.
Grifols, S.A. researches, develops, and produces plasma-derived medicines and diagnostic equipment for healthcare markets worldwide. Headquartered in Barcelona, Spain, the company operates across segments including biopharmaceuticals, diagnostics, and bio supplies, providing essential therapies and medical solutions to hospitals and biotech firms.
What to Watch at GRFS
This filing looks backward at holdings from the end of the reporting period and may not reflect the investor's current position. Investors will look to upcoming filings and the company's next earnings report on February 25, 2027, for further updates on the business.
Related Filing Alerts
Source: Brandes Investment Partners's 13F filing on $GRFS (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Brandes Investment Partners 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts